Skip to content

Gynecologic Endoscopic Surgery of Female Motion Sickness Patients

Application of Remifentanil Target Controlled Infusion Combined With Ibuprofen Injection in Gynecologic Endoscopic Surgery of Female Motion Sickness Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06232785
Enrollment
66
Registered
2024-01-31
Start date
2022-02-01
Completion date
2023-12-01
Last updated
2024-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ibuprofen, Motion Sickness, Postoperative Nausea and Vomiting

Brief summary

The goal of this clinical trial is to compare the analgesic effect of sufentanil and ibuprofen and the incidence of vomiting, and to choose better postoperative analgesic drugs for motion sickness patients.in describe participant population. The main questions it aims to answer are: * Whether this anesthesia method can meet the analgesic needs of gynecological laparoscopic surgery. * Whether this anesthesia method can reduce the incidence of nausea and vomiting in patients with motion sickness after gynecological laparoscopic surgery. Participants will use target-controlled infusion anesthesia combined with 0.8g ibuprofen injection. Researchers will compare with use of target-controlled infusion combined with sufentanil to see if the incidence of nausea and vomiting is higher.

Detailed description

Abstract: Objective: To compare the analgesic effect of sufentanil and ibuprofen and the incidence of vomiting, and to choose better postoperative analgesic drugs for motion sickness patients. Methods: Sixty-eight female patients aged between 18 and 60 years with motion sickness were selected for gynecologic endoscopic surgery under general anesthesia. Sixty-eight female patients were randomly divided into two groups, Group B (ibuprofen group) and Group S (sufentanil group), using a random number table method. The initial plasma target concentration of propofol was set at 4ug/ml and adjusted using the titration method. Once the patient lost consciousness, the target concentration of remifentanil was set at 4ng/ml and rocuronium at 0.6mg/kg, followed by endotracheal intubation three minutes later. During the operation, the plasma target concentration of propofol was maintained at 5ug/ml and remifentanil at 4ng/ml, with adjustments made based on stress reaction levels. General anesthesia was sustained through continuous administration of rocuronium at doses of 5 µg/kg/min. In Group B (ibuprofen group), intravenous administration of ibuprofen (0.8g) took place within half an hour before the end of surgery; in Group S (sufentanil group), intravenous injection of sufentanil (0.2ug/kg) occurred half an hour before completion of the operation, along with intravenous injection of dexamethasone (5mg) five minutes prior to anesthesia induction to prevent postoperative nausea and vomiting in both groups. The following data were collected: duration of operation, pneumoperitoneum time, extubation time, respiratory recovery time; Incidence of postoperative nausea and vomiting at different time intervals: Postanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Visual analogue pain score : Postanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Frequency of use of analgesics and antiemetic drugs; Incidence of adverse reactions within 24 hours after surgery; Postoperative satisfaction.

Interventions

DRUGIbuprofen

0.8g intravenous injection 30min before the end of the operation

DRUGsufentanil

0.2ug/kg intravenous injection 30min before the end of the operation

Sponsors

Second Hospital of Jilin University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 18-60 years old; 2. Class I - II patients according to the American Society of Anesthesiologists classification; 3. Body mass index : 20-27kg/㎡; 4. non-life-threatening diseases of heart, lung, brain, liver, kidney and other important organs; 5. No recent use of sedatives, opioids, non-steroidal drugs such as ibuprofen, antiemetic drugs. 6. No history of digestive tract ulcer; 7. Motion sickness patients undergoing gynecological endoscopic surgery under general anesthesia. 8. Postoperative analgesia pump is not required.

Exclusion criteria

1. Low weight, poor general state; 2. general anesthesia drug allergy; 3. Long-term use of painkillers, antiemetic drugs, or use of opioids within 12 hours before surgery.

Design outcomes

Primary

MeasureTime frameDescription
Comparison of postoperative nausea and vomiting between the two groupsFrom the end of surgery until 24 hours after surgeryIncidence of postoperative nausea and vomiting at different time intervals: Pstanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); postoperative nausea and vomiting grading 24h after surgery: According to the severity of postoperative nausea and vomiting, postoperative nausea and vomiting was divided into 1-4 grades. Grade I: no nausea or vomiting; Grade II: mild nausea, abdominal discomfort, but no vomiting; Grade III: obvious vomiting, but no contents of the vomit; Grade IV: Severe vomiting with gastric juices and other contents. Postoperatively PONV is considered to occur in patients with grade II or higher
Visual Analogue Score scores in postoperative resting state of patients in two groupsFrom the end of surgery until 24 hours after surgeryVisual analogue pain score : Pstanesthesia care unit residence period (T1), 0-3h after extubation (T2), 3-6h after extubation (T3), 6-12h after extubation (T4), 12-24h after extubation (T5); Pain score 24h after operation: Pain Assessment Scale was used to evaluate the analgesic effect of the two groups. 0 doesn't hurt; 1 to 3 points - mild pain; 4 to 6 points - moderate pain; Score 7-10 - severe pain
Comparison of vomiting between the two groupsFrom the end of surgery until 24 hours after surgeryPostoperative vomiting score 24 hours after surgery: Postoperative vomiting was divided into 0-3 points according to the degree of vomiting. 0 score: no vomiting; 1 point: vomiting 1-2 times; 2 points: vomiting 3 to 5 times; 3 marks: vomiting \> 5 times

Secondary

MeasureTime frameDescription
Extubation timeOne minute after surgerythe time from cessation of propofol and remifentanil infusion at the end of surgery to withdrawal of tracheal catheter
Respiratory recovery timeOne minute after surgerythe time from the end of surgery when propofol and remifentanil infusion were stopped to the time when patients resumed breathing on their own
Volume of fluids and blood lossFrom the beginning to the end of the surgeryIntraoperative condition
Score of patient satisfactionFrom the end of surgery until 24 hours after surgeryPatient satisfaction score: 0: very satisfied, 1: average, 2: unsatisfactory. A score of more than 1 is considered poor satisfaction
Occurrence of adverse reactionsWithin 24 hours of extubationThe incidence of postoperative adverse reactions such as dizziness, headache, agitation, respiratory depression and skin pruritus were compared between the two groups
Time of pneumoperitoneumFrom the beginning to the end of the surgeryIntraoperative condition
Time of operationFrom the beginning to the end of the surgeryIntraoperative condition

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026